We aim to discover, develop, and commercialize novel drugs with the potential to cure challenging infectious diseases, focusing initially on a functional cure for chronic HBV and on a new class of medicines that uses our patent pending microbiome technologies to treat disease in entirely new ways.

Derek Small

Derek Small

President & Chief Executive Officer, Director

Mr. Small serves as Assembly’s President and Chief Executive Officer. He assumed the role in February 2015. Previously, he served as President and Chief Operating Officer of Assembly Pharmaceuticals, which was acquired by assembly biosciences through a merger in 2014. Mr. Small co-founded Assembly Pharmaceuticals to develop curative therapies for chronic HBV infection and served as its Executive Chairman and Chief Executive Officer since its inception in 2012 until its acquisition. Previously, he served as a founding director, President and Chief Executive Officer of Naurex, a privately held company developing novel therapies for central nervous system (CNS) disorders whose clinical assets were acquired by Allergan in 2014. At Naurex, Mr. Small spearheaded the development of a rapidly acting novel antidepressant drug, rapastinel, which has since earned a coveted “breakthrough” designation from the FDA. Naurex's preclinical programs formed the basis for a spinout CNS company, Aptinyx. From 2009 to 2012, Mr. Small also served as a founding director, President and Chief Executive Officer of privately held biotechnology company Coferon, which is developing a novel self-assembling chemistry platform with transformative potential. Assembly Pharmaceuticals, Naurex/Aptinyx and Coferon are portfolio enterprises of Luson Bioventures a venture creation firm that Mr. Small founded in 2007 and continues to head. Earlier in his career, he was a co-founder and served as Head of Business and Corporate Development and directed regulatory and clinical affairs at Semafore Pharmaceuticals, which pioneered one of the first PI3K kinase cancer programs to advance into clinical trials. Mr. Small received a BS in Business from Franklin College, and studied global business at the Harlaxton College affiliate program in England.

Graham Cooper

Graham Cooper

Chief Financial Officer and Chief Operating Officer

Graham Cooper was the Chief Financial Officer of Receptos from 2013 until its sale in 2015 to Celgene. Prior to joining Receptos, during 2012, Mr. Cooper was the Chief Financial Officer of Geron Corporation, a biopharmaceutical company focused on cancer therapies. From 2006 until 2011, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, a biotechnology company focused on obesity therapies. From 1999 to 2006, Mr. Cooper held positions of increasing responsibility including Director, Health Care Investment Banking, at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From 1992 to 1995, he worked as an accountant at Deloitte & Touche, where he earned his CPA. Currently, Mr. Cooper serves as a Director of the Board of Bioniz Therapeutics, Kezar Life Sciences and Unity Biotechnology. Mr. Cooper holds a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.

Richard Colonno

Richard Colonno, PhD

Executive Vice President & Chief Scientific Officer of Virology Operations

Dr. Colonno is an internationally recognized expert with over 35 years of experience in antiviral drug discovery and development. He joins Assembly from Presidio Pharmaceuticals, where he served as Chief Science Officer and directed the company’s hepatitis C (HCV) antiviral programs, including the discovery and development of the HCV NS5A inhibitor ravidasvir. Prior to Presidio, Dr. Colonno was Vice President, Infectious Diseases Drug Discovery at Bristol-Myers Squibb Co., where he played a pivotal role in building the company’s existing antiviral franchise, including the discovery, development and approval of entecavir (Baraclude®) for HBV and atazanavir (Reyataz®) for HIV. Earlier, he was Senior Director of Antiviral Research at Merck Research Labs following research positions at DuPont’s Experimental Station and the Roche Institute of Molecular Biology. Dr. Colonno received a BA in Biology and Chemistry from Kansas Wesleyan University, a PhD in Microbiology from the University of Kansas and has co-authored more than 160 scientific articles.

Uri Lopatin

Uri Lopatin, MD

Chief Medical Officer

Dr. Lopatin joined Assembly as Chief Medical officer in July 2014 upon the acquisition of Assembly Pharmaceuticals by merger. Dr. Lopatin was a co-founder of Assembly Pharmaceuticals, where he served as Chief Medical Officer and Vice President Research and Development since October 2012. Prior to Assembly, he was a Senior Director for Clinical and Translational Research in Liver Disease at Gilead Sciences. Prior to Gilead, Dr. Lopatin was a Translational Medical Leader at Roche focused on chronic infectious diseases and immunology. Earlier, he was an Associate Director in Hepatology at Schering-Plough. Dr. Lopatin has published extensively, specifically on HBV and immunology, and is a co-author of multiple patents for the diagnosis and treatment of viral hepatitis. Dr. Lopatin was a mentor in the Thiel 20 Under 20 Fellowship and a Fellow in the UPMC Emerging Leaders in Biosecurity Initiative. Dr. Lopatin graduated cum laude with distinction from Cornell University and received his MD degree from the University of Medicine and Dentistry-New Jersey Medical School, where he was awarded the Stanley S. Bergen medal of excellence. Dr. Lopatin received his infectious disease Board certification following fellowship training at the National Institutes of Health, and internal medicine Board certification following completion of residency at New York University.

Jackie Papkoff

Jackie Papkoff, PhD

Senior Vice President,
Chief Scientific Officer Microbiome

Dr. Papkoff has worked in both pharma and biotech for over 20 years and has broad scientific strategy, executive leadership and business experience. She has deep expertise in cell biology and molecular mechanisms of disease which she has applied to therapeutic and biomarker preclinical discovery & development in oncology, inflammation and autoimmunity. Prior to joining Assembly Biosciences, Dr. Papkoff was Senior Vice President Research at Evelo Biosciences where she led the preclinical scientific team to discover, validate and nominate microbial therapeutics for clinical development in oncology indications. Prior to Evelo Dr. Papkoff was a founding member of the J&J California Innovation Center where she served as Vice President of Immunology Scientific Innovation for the Janssen Immunology Therapeutic Area focused on inflammatory and autoimmune diseases. Previously, she was CSO of CFD Therapeutics, a cancer-immunology focused antibody therapeutics company she co-founded, and held R&D leadership positions at diaDexus, and Aventis pharma. Dr. Papkoff has a BA in Biology from University of California Santa Cruz, a PhD in Biology from University of California San Diego & the Salk Institute and was a postdoctoral fellow at Stanford and University of California San Francisco.

Elizabeth Haber Lacy

Elizabeth Haber Lacy

General Counsel,
Corporate Secretary

Ms. Lacy has over 20 years of legal experience in the areas of corporate and entrepreneurial services, venture and corporate financings, private equity transactions, mergers and acquisitions, general corporate counseling and commercial transactions. Ms. Lacy joined Assembly in December 2015 as General Counsel, Vice President of Legal Operations and became Corporate Secretary in April 2016. Prior to joining Assembly, Ms. Lacy was a partner with Barnes & Thornburg LLP. Prior to that, she was a partner with Leagre, Chandler & Millard and earlier in her career, Ms. Lacy worked at Chicago law firms Kirkland & Ellis and Jones, Day, Reavis & Pogue. Ms. Lacy was selected for inclusion in The Best Lawyers in America® in 2011-2015 and was named “Lawyer of the Year” in 2013 in the area of venture capital law. She received an AB in Public Policy from Duke University and a JD from the Case Western Reserve University School of Law, where she graduated summa cum laude and was elected to the Order of the Coif. Ms. Lacy is a member of the Indiana and Illinois state bars.

Wayne Haber Lacy

Wayne Herber, PhD

Senior Vice President,
Biological Manufacturing

Dr. Herber is a microbiologist with almost 30 years of experience in the scale-up and manufacture of a wide range of vaccines and other biologics, as well as antibiotics and secondary metabolites. Prior to Assembly, Dr. Herber was Senior Director, Manufacturing Science & Technology at AstraZeneca Biologics. Previously, Dr. Herber was Vice President, Process and Product Development at Auxilium Pharmaceuticals. For more than 20 years, Dr. Herber held positions of increasing responsibility at Merck & Co., starting as Senior Research Microbiologist and progressing to Senior Director for Bioprocess R&D, Fermentation & Cell Culture, and Director/Distinguished Scientist for Vaccine Process Development. He received a BS from the University of Delaware and a PhD from Rutgers University. Dr. Herber completed post-doctoral studies at Georgetown University School of Medicine.

Micah Mackison

Micah Mackison

Senior Vice President,
Corporate Development & Strategy

Mr. Mackison has over 15 years of pharmaceutical and life sciences experience in corporate development and strategy, mergers and acquisitions and finance. Prior to Assembly, he was Senior Director, Corporate Investment Life Sciences for Jabil, where he was responsible for healthcare M&A and venture investments. Prior to Jabil, Mr. Mackison founded and served as Managing Director of Oakridge Bioventures, a pharmaceutical strategy and M&A advisory firm, where he advised and co-founded startup companies. Previously, Mr. Mackison served as Divisional Director of Corporate Strategy and Senior Director, New Ventures at Lundbeck in Copenhagen. Prior to Lundbeck, Mr. Mackison was Director, Corporate Development and M&A with Ovation Pharmaceuticals, which was acquired by Lundbeck in 2009. Earlier in his career, Mr. Mackison held positions of increasing responsibility in finance at Pfizer and Eli Lilly and Co. He earned a BS in Finance from Indiana University.

Jennifer Troia

Jennifer Troia, MHROD, SPHR, SHRM-SCP

Senior Vice President,
Human Resources and Organization Development

Ms. Troia has over 25 years of Human Resources experience in the Life Sciences industry, ranging from start-ups through commercialized organizations. Prior to joining Assembly Biosciences in May 2017, she had re-joined Sunesis Pharmaceuticals in December 2013, after spending over four years consulting for multiple organizations in therapeutics and diagnostics. Prior to that, Ms. Troia spent a year as Vice President, Human Resources, at CoMentis. Ms. Troia served as Vice President, Human Resources and Corporate Operations at Sunesis Pharmaceuticals between January 2001 and August 2008, where she held leadership positions of increasing responsibility. She worked with COR Therapeutics between 1996 and 2001, playing a pivotal role in hiring a national sales force of more than 100 employees. Previously, she held positions at Gilead Sciences as well as in the high technology and investment banking industries. Earlier, she was employed at 3M for seven years. Ms. Troia has been serving on the Board of Directors of the Bay Area Human Resource Executives Council (BAHREC) since 2004. She is a certified member of the Society for Human Resource Management (SHRM-SCP). She is also a member of the Northern California Human Resource Association. Ms. Troia holds a Masters in Human Resources and Organization Development from the University of San Francisco.

William Ringo

Chairman of the Board,
Non-Executive

Mr. Ringo became a director in July 2014, following the Assembly Pharmaceuticals acquisition, and was named non-executive Chairman in 2015. From 2010 until 2015, Mr. Ringo served as a Senior Advisor at Barclays Capital, the global investment banking division of Barclays Bank PLC, and also as Strategic Advisor at Sofinnova Ventures, a life sciences-focused investment firm. Previously, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer. Prior to joining Pfizer, Mr. Ringo was President and Chief Executive Officer of Abgenix, a public biotechnology company later acquired by Amgen. His experience in the global pharmaceutical sector also includes nearly 30 years with Eli Lilly and Co., where he held a number of executive roles and was a member of Lilly’s operating committee. Mr. Ringo currently serves as a director of Immune Design, Dermira and Five Prime Therapeutics. He previously served as a director of Sangamo Biosciences, Mirati Technologies and Onyx Pharmaceuticals. Mr. Ringo received a BS in Business Administration and an MBA from the University of Dayton.

Anthony Altig

Director

Mr. Altig has been a director since 2012. From 2008 to December 2017, he was the Chief Financial Officer of Biotix Holdings, a manufacturer of microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa (subsequently Verenium), a public company developing specialized industrial enzymes. Previously, Mr. Altig was the Chief Financial Officer of Maxim Pharmaceuticals, a public biopharmaceutical company. In addition, Mr. Altig serves as a director and Chairman of the audit committee for TearLab (formerly OccuLogix) a publicly traded eyecare technology company. He formerly served as a director of MultiCell Technologies and Optimer Pharmaceuticals, a public company, until its acquisition by Cubist Pharmaceuticals. Mr. Altig holds a BBA in Business from the University of Hawaii and is a Certified Public Accountant (inactive).

Mark Auerbach

Director

Mr. Auerbach has been a director since 2010. From 2014 until 2016, he was non-executive Chairman and from 2013 until 2016, he was audit Chairman of RCS Capital Corporation, a publicly traded financial services company. Mr. Auerbach was formerly the Chairman of Neuro-Hitech, an early-stage pharmaceutical company. He was also lead independent director and Chairman of the audit committee of Optimer Pharmaceuticals, a public company, until its acquisition by Cubist Pharmaceuticals. Over the past 20 years, Mr. Auerbach has served as a director for several other companies, including Par Pharmaceutical Companies, a publicly traded manufacturer and marketer of generic pharmaceuticals and the parent of Par Pharmaceutical. He received a BS in Accounting from Rider University.

Richard DiMarchi, PhD

Director

Dr. DiMarchi became a director in July 2014 following of the acquisition of Assembly Pharmaceuticals, which he co-founded and served as a founding director. Dr. DiMarchi currently holds the Cox Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University (currently on leave of absences until January 2020) and serves as Vice President of Research at Novo Nordisk Research Labs. Dr. DiMarchi was a co-founder and board member of biotechnology companies Ambrx, and Marcadia Biotech a founder of Calibrium LLC, and advisor to Twilight Ventures. Dr. DiMarchi previously served as a director of Isis and Millennium BioTherapeutics, as well as board member of the biotechnology trade group BIO. Dr. DiMarchi contributed significantly to the discovery of the first insulin analog, Humalog®, and to the commercial development of major pharmaceutical products such as Humulin®, Humatrope®, Glucagon®, Xigris®, Forteo® and Evista®. He is the recipient of numerous awards and has been inducted into the National Inventors Hall of Fame and the National Academy of Medicine. Dr. DiMarchi received a BS with honors from Florida Atlantic University and a PhD in Biochemistry from Indiana University. He completed postdoctoral studies at The Rockefeller University.

Myron Z. Holubiak

Director

Mr. Holubiak has been a director since 2010. He serves as President, Chief Executive Officer and a director of Citius Pharmaceuticals a late stage drug development company focused on critical care drug products, and successor by merger to Leonard-Meron Biosciences. Mr. Holubiak is the former President of Roche Laboratories, USA, a major research-based pharmaceutical company, where he held executive, operational and sales and marketing position during a 19-year tenure. From September 2002 until June 2016, Mr. Holubiak served on the board of directors of BioScrip, a publicly traded company and a leading home infusion provider with nationwide pharmacy and nursing capabilities and was chairman of the board of Bioscrip from April 2012 until June 2016. From May 2007 to January 2014, Mr. Holubiak was president of 1-800-DOCTORS, a private physician finder company and a member of its board of directors until September 2017. Mr. Holubiak is a director of bioAffinity Technologies, a private cancer screening and diagnostics company, and former director of Intellicell Biosciences a publicly traded regenerative medicine company. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation and a Lifetime Honorary Member of AMCP. Mr. Holubiak received his BS in Molecular Biology and Biophysics from the University of Pittsburgh. Mr. Holubiak has received advanced business training from the Harvard Business School, the London School of Economics and the Centre for Health Economics at the University of York.

Helen S. Kim

Director

Ms. Kim joined as a director in 2018 and has over 25 years' experience in leadership roles in biotechnology, most recently as Executive Vice President of Business Development at Kite Pharma. She led the acquisition of Kite Pharma by Gilead in September 2017. Ms. Kim served as Strategic Advisor of NGM Biopharmaceuticals from January 2012 through January 2014. Ms. Kim served as the Chief Business Officer at NGM Biopharmaceuticals from August 2009 to January 2012. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences where she restructured and repositioned the company prior to successfully negotiating its sale to Bristol-Myers Squibb in 2008. Ms. Kim's additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms. Kim recently served as Chief Program Officer for the Gordon and Betty Moore Foundation. Currently, she serves as a director for Exicure, a public company, and private companies Peloton Therapeutics and Applied Molecular Transport. Ms. Kim received a BS in Chemical and Biomedical Engineering from Northwestern University and a MBA from the University of Chicago.

Alan J. Lewis, PhD

Director

Dr. Lewis joined as a director in December 2015. He is currently President, Chief Executive Officer and director of Diavacs, a private biotechnology company that offers dendritic cell therapy for autoimmunity and juvenile diabetes, which he joined after serving as Chief Executive Officer and a director of Medistem, a public biotechnology company that is a developer of stem cell therapies, which was acquired by Intrexon. Previously, Dr. Lewis was Chairman, President and CEO of cancer drug developer Ambit Biosciences, which was subsequently acquired by Daiichi Sankyo Company. Prior to Ambit, Dr. Lewis was President and CEO of the Juvenile Diabetes Research Foundation and President and CEO of private stem cell company Novocell. Prior to Novocell, Dr. Lewis served as CEO and a director of Signal Pharmaceuticals until its acquisition by Celgene. Dr. Lewis was then named President of Celgene’s Signal Research division in San Diego, where he directed its integrated drug discovery program in oncology and inflammation and served on Celgene’s corporate executive committee. Dr. Lewis also is on the board of directors for NASDAQ-listed BioMarin Pharmaceuticals, where he chairs the science and technology committee and the board of directors of Scancell Holdings Plc, where he serves on the audit committee and remuneration committee. Earlier in his career, Dr. Lewis held positions of increasing responsibility at Wyeth-Ayerst Research, eventually serving as Vice President of Research with responsibility for 550 scientists and staff. Dr. Lewis has contributed to advancing more than 20 molecules into clinical development and overseeing five investigational drugs that reached the market. He has co-authored over 100 peer-reviewed publications and is an inventor on several patents. Dr. Lewis holds a BSc in Physiology and Biochemistry from the University of Southampton and a PhD in Pharmacology from the University of Wales. He completed postdoctoral training at Yale University.

Sue Mahony, PhD

Director

Dr. Mahony has been a director since December 2017. She currently serves as president, Lilly Oncology, a senior vice president, Eli Lilly and Company, and a member of the company’s Executive Committee. Prior to that, she was senior vice president, human resources and diversity. Dr. Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe in oncology/hematology and cardiovascular medicine for Schering-Plough, Amgen and Bristol-Myers Squibb with global and direct responsibility for the US, Japan, China, Europe and Canada. Since joining Lilly, Dr. Mahony has held roles in global marketing, product development, six sigma and general management, including global brand development leader for duloxetine (Cymbalta®) and fluoxetine (Prozac®), and country manager for Canada. Dr. Mahony earned both Bachelor of Science and PhD degrees in pharmacy from Aston University in the UK, which also awarded her an honorary doctorate degree. She received an MBA from the London School of Business, and in 2010, she was recognized as one of the Indianapolis Business Journal’s “Women of Influence.”

Derek Small

President & Chief Executive Officer, Director

Mr. Small serves as Assembly’s President and Chief Executive Officer. He assumed the role in February 2015. Previously, he served as President and Chief Operating Officer of Assembly Pharmaceuticals, which was acquired by assembly biosciences through a merger in 2014. Mr. Small co-founded Assembly Pharmaceuticals to develop curative therapies for chronic HBV infection and served as its Executive Chairman and Chief Executive Officer since its inception in 2012 until its acquisition. Previously, he served as a founding director, President and Chief Executive Officer of Naurex, a privately held company developing novel therapies for central nervous system (CNS) disorders whose clinical assets were acquired by Allergan in 2014. At Naurex, Mr. Small spearheaded the development of a rapidly acting novel antidepressant drug, rapastinel, which has since earned a coveted “breakthrough” designation from the FDA. Naurex's preclinical programs formed the basis for a spinout CNS company, Aptinyx. From 2009 to 2012, Mr. Small also served as a founding director, President and Chief Executive Officer of privately held biotechnology company Coferon, which is developing a novel self-assembling chemistry platform with transformative potential. Assembly Pharmaceuticals, Naurex/Aptinyx and Coferon are portfolio enterprises of Luson Bioventures, LLC, a venture creation firm that Mr. Small founded in 2007 and continues to head. Earlier in his career, he was a co-founder and served as Head of Business and Corporate Development and directed regulatory and clinical affairs at Semafore Pharmaceuticals, which pioneered one of the first PI3K kinase cancer programs to advance into clinical trials. Mr. Small received a BS in Business from Franklin College, and studied global business at the Harlaxton College affiliate program in England.